News Center
Industry Trends
2025 Academic Committee Meeting of the Laboratory of Natural Drug Discovery and Industrialization Successfully Held
The 2025 Academic Committee Meeting of the Laboratory for Natural Drug Discovery and Industrialization was successfully held recently in Meeting Room N502 at Macao University of Science and Technology (MUST). The meeting was chaired by Academician Yang Baofeng of the Chinese Academy of Engineering and renowned pharmacologist, and led by
Top-Tier Journal Research: Garlic Outperforms Metformin in Longevity Extension
html On December 19, 2025, the University of Seville in Spain published a research paper in the journal Cell Metabolism. This study is the first to demonstrate in mammals that diallyl sulfide (H2S) from garlic can continuously generate hydrogen sulfide through non-enzymatic pathways, extending mouse lifespan by 11.4%—a greater extension
In Less Than a Month, Marketing Applications for Over 100 Generic Drugs Rejected
Recently, the National Medical Products Administration (NMPA) has been frequently publishing delivery notices for drug notification letters on its official website. Generally speaking, delivery of such a notification letter indicates that a marketing authorization application has been “not approved,” or that the applicant has proactively withdrawn the application after anticipating
Macao University of Science and Technology (MUST) team led by Academician Zhu Yizhun, Associate Professor Guo Hui, and Associate Professor Wang Xiaolin publishes in Biomaterials: biomimetic nanoplatform overcomes intra-articular hypoxia to potentiate photodynamic therapy for rheumatoid arthritis
Rheumatoid arthritis (RA) is a complex autoimmune disease with an insidious course that can progressively erode joints, leading to swelling, pain, deformity, and even disability, affecting nearly 1% of the global population. At present, clinical management of RA mainly relies on antirheumatic drugs, nonsteroidal anti-inflammatory drugs (NSAIDs), glucocorticoids, and biologics.
China’s innovative-drug BD now accounts for nearly half of global deal flow, yet per-capita spend is only 1/124 of the U.S.: how can Chinese pharma chart a path to an Eli Lilly–scale, trillion-dollar valuation?
①The capital ecosystem in the pharmaceutical industry is undergoing a profound shift, with BD financing surpassing the primary market to become a core source of cash flow for many innovative drug companies;②While China’s innovative drugs are strong in outbound BD and global partnering, the domestic market still lags significantly—per capita
The global community is awaiting China’s next-generation innovative medicines.
This July, China’s pharmaceutical community was ignited by a blockbuster deal worth tens of billions of dollars. Hengrui Pharma struck a USD 12.5 billion partnership with global pharmaceutical giant GlaxoSmithKline to co-develop up to 12 innovative medicines, setting a new record for China’s innovative-drug “going global” efforts. Just one month
M.U.S.T. Academician Zhu Yizhun Wins First Place in the Biomedical Start-up Group at the 13th China Innovation & Entrepreneurship Competition
Held from November 18 to 21, 2024, in Taizhou, Jiangsu, the National Finals of the 13th China Innovation & Entrepreneurship Competition operated under the theme "Gathering for Innovation, Moving Towards the New." The project titled "Discovery and Clinical Research of Original Anti-inflammatory and Immune Drugs," led by Academician Zhu Yizhun—Associate